Perhaps, in the next three years, we will see the following happen to the new Biota company:
+ Lani ROW is progressing as planned and the US government pre-solicitation orders placed for Lani.
+ Vapendavir is licensed to a third party for a big upfront payment plus >10% royalties
+ Gyrase program gets the US government funding for further developement
+ HEP C programs are advanced into clinical stage.
Just my wishes. LOL.....
